Summary Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-ras oligonucleotide hybridization in 78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal ovaries. A cut-off value of an integral of absorbance (i.a.) of 2.20, obtained by receiver operating characteristic (ROC) curve, was shown to be the best cut-off for defining p21 positivity. p21 levels were higher in malignant tumours than in benign tumours (median 2.10 i.a. vs median 1.22 i.a.; P= 0.014) and in omental metastases than in primary ovarian carcinomas (median 2.54 i.a. vs median 2.1 i.a.; P= 0.0089). p21 overexpression did not correlate with any of the clinicopathological parameters examined. Follow-up data were available for 63 patients. A significant relationship was shown between p21 positivity and a shorter overall survival (OS) (P < 0.03) and progression-free survival (PFS) (P< 0.03). In multivariate analysis only the presence of ascites, p21 levels and epidermal growth factor receptor status retained an independent prognostic role. K-ras gene mutations were frequently detected in benign and low malignant potential tumours (71.4%), which were mostly mucinous (P= 0.01 52).
The prognostic characterization of patients with ovarian cancer, which is at present based mostly on stage, volume of residual tumour mass after cytoreductive surgery and presence or absence of ascites (as defined by the International Federation of Gynecology and Obstetrics, FIGO), is still inadequate. After optimal surgical debulking and a pathologically complete response (CR) to primary chemotherapy, tumour will recur and lead to death in about 50% of patients (Copeland and Gershenson, 1986) . Therefore, the identification of new biological factors that are more closely related to tumour cell biology and aggressiveness may help to permit the prompt identification of patients with a particularly poor prognosis.
Several studies have already shown that genetic alterations may lead to uncontrolled proliferation by activating oncogenes or inactivating tumour-suppressor genes. The most extensively studied oncogenes in the former group include cellular ras proto-oncogenes, which are involved in the control of cell growth and proliferation and, in the activated form, are associated with cell transformation and induction of metastasis (Egan et al, 1987 (Egan et al, , 1989 Caulin et al, 1996) . The ras family consists of three members, N-, H-and K-ras, which code for highly homologous proteins with a molecular weight of 21 kDa and are believed to function as signal switch molecules. In the active GTP-bound conformation, they transmit a signal to an effector molecule, thus leading to cell proliferation. The transforming potential of p21 has been related mainly to point mutations that are usually found in codons 12, 13 and 61.
Many studies have demonstrated that ras molecular alterations may prove useful in predicting the clinical behaviour of some malignancies, including breast (Bland et al, 1995) , lung (Rosell et al, 1993) and endometrial (Mizuuchi et al, 1992) cancer. In particular, overexpression of the ras/p21 oncoprotein in breast cancer appears to be significantly correlated with advanced tumour stage and axillary lymph node involvement, suggesting that increased p21 expression is associated with tumour progression and poor prognosis. Ras overexpression is thought to be a common occurrence in ovarian cancer (Slamon et al, 1984; O'Brien et al, 1989) , although its prognostic role is still controversial (Rodenburg et al, 1988; Scambia et al., 1993a; Katsaros et al, 1995) . In a previous study, we reported the association of p21-enhanced expression with the malignant phenotype and the acquisition of metastatic potential in ovarian cancer (Scambia et al, 1993a) . Because of the small number of cases examined and the short follow-up, only a preliminary evaluation of the prognostic value of p21 was then possible.
In this study, the role of p21 protein as a new prognostic factor in epithelial ovarian cancer was investigated for the first time on a large single-institution patient population with a long-term follow-up. The correlation between p21 levels and the presence of epidermal growth factor receptor (EGFR), which has been reported to be associated with a poor prognosis in ovarian cancer (Scambia et al, 1992 (Scambia et al, , 1995 Bartlett et al, 1996) , was also examined. Moreover, in order to investigate whether ras gene mutation assessment could improve the prognostic information provided by p21 oncoprotein levels, mutations of Kras -the ras gene prevalently mutated in ovarian tumours (Enomoto et al, 1990; Teneriello et al, 1993 ) -were studied in the same population.
MATERIALS AND METHODS Samples
All the specimens analysed in this study were (WHO, 1979) . About 28 days after the last course, clinically complete responders underwent second-look laparoscopy. In laparoscopy-negative cases, second-look laparotomy was performed for the assessment of pathological response. During laparotomy and after peritoneal washings and careful inspection of the abdominal cavity, biopsy of all suspicious lesions was performed, along with several random biopsies. Patients who had had initially only an explorative laparotomy underwent a second laparotomy after chemotherapy, and a second cytoreduction was attempted. Pathologically complete responders received no further therapy, and all the other patients were treated according to ongoing phase II studies (Benedetti Panici et al, 1990 ). incubated at 4°C in the same buffer containing Y13-259 monoclonal antiserum (Oncogene Science, New York, NY, USA) (diluted 1:300) for 4 h, with rabbit anti-rat IgG (diluted 1:500) for 2.5 h and finally with Sx 106 c.p.m. ml- ['251 ]protein A for 1 h. MAb Y13-259 is a rat-derived monoclonal antibody directed against Harvey murine sarcoma virus (Ha-MSV)-encoded p21 and reacts with both the point-mutated and normal products of the ras gene family (H-,N-,K-ras). Filters were exposed to Kodak XAR films (Eastman Kodak, Rochester, NY, USA) for 48 h at -80°C. Computer-aided image analysis of autoradiographs was performed to quantify the intensity of the bands. A p21 control derived from normal rat kidney cells transformed by Ha-MSV was included in all experiments.
Densitometric values of the band intensities, expressed as integral of absorbance (i.a.), were used for statistical analysis. In a few cases, Western blot analysis was performed in different specimens of the same tumour sample to determine the intratumour homogeneity of p21 expression (coefficient of variation 18%).
To correlate the expression of p21 with survival data, an i.a. of 2.20 was shown by the receiver operating characteristic (ROC) curve (Hanley and McNeil, 1982) to be the best cut-off value for defining p21 status (data not shown).
DNA preparation
Tumour specimens were stored at -70°C until analysis. Genomic DNA extraction from fresh tissue was performed following standard procedures (Sambrook et al, 1989) . If fresh material was not available, DNA was extracted from paraffin-embedded sections (28 cases). DNA preparation from paraffin-embedded tissues was performed by incubating 10-jm-thick sections in 0.5 ml of a buffer containing 10 mM Tris pH 8.3, 50 mm potassium chloride, 1.5 mm magnesium chloride, 100 jig ml' BSA, 1% Tween 20, 0.45% Nonidet P-40 and 100 jg ml' proteinase K at 55°C for 16 h. The samples were then boiled for 5-10 min and cooled on ice. Five microlitres of a 1:10 dilution were used for polymerase chain reaction (PCR).
Polymerase chain reaction
The following primers were used to examine codons 12, 13 and 61 of K-ras:
Detection of p21 protein Tumour specimens were stored at -70°C until analysis. Frozen samples were pulverized and homogenized with five volumes of ice-cold buffer containing 20 mm Tris-HCl, 100 mm sodium chloride, 5 mm magnesium chloride, 1% Nonidet-P40, 0.5% sodium deoxycholate and 2 kallikrein inhibitor units per ml of bovine aprotinin. The homogenate was centrifuged at 750 g for 20 min at 4°C, and the resulting supernatants were frozen at -80°C before using. Protein concentration was determined by the method of Bradford (1976) with Kabi solution (10% human albumin) as a standard: 100 jg of each sample were separated by 12% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis, transblotted onto nitrocellulose filters and processed essentially as described (Scambia et al, 1993a) . Briefly, filters were incubated for 3 h at 37°C in TEN-NP40 buffer (50 mm Tris-HCl, pH 7.5, 2 mm EDTA, 150 mm sodium chloride, 0.1% Nonidet-P40) with 3% bovine serum albumin (BSA). Then the filters were sequentially K-ras (KA12/13): K-ras (KB 12/13): K-ras (KA61): K-ras (KB61):
PCR analysis was performed in the presence of 0.5 jig of genomic DNA template, following the manufacturer's recommendations (Gene Amp, Perkin Elmer, Branchburg, NJ, USA). The analysis was carried out in a thermal cycler (Perkin-Elmer/Cetus 9600) for 35 cycles. Each cycle consisted of denaturation at 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 1 min. The products were analysed by electrophoresis on 2% agarose gels.
Oligonucleotide hybridization A 15-ml aliquot of each PCR product was transferred to a nylon filter (NEN Dupont, Bad Homburg, Germany) using a slot-blot British Journal of Cancer (1997) 75 (10), [1547] [1548] [1549] [1550] [1551] [1552] [1553] Ras/p21 in human ovarian cancer 1549 minifold apparatus (Schleicher and Schuell, Dassel, Germany) The filters were washed in 3 M tetramethylammonium chloride (Wood et al, 1985) . Autoradiography was performed at -80°C for 1 h using Konica AX films (Konica, Tokjo, Japan). EGFR and DNA ploidy evaluation Radioreceptorial assessment of EGFR expression was performed on 68 primary ovarian cancers as described by Scambia et al (1992) . An EGFR level of 1.5 fmol mg-' protein was chosen as the cut-off value to define EGFR status. DNA ploidy was evaluated using an Epics XL cytofluorimeter as previously described (Scambia et al, 1993b Kaplan and Meier (1958) , and the curves were examined by means of the log-rank test (Mantel, 1966) . Multivariate analysis was performed according to the Cox proportional hazards model with backward stepwise procedure (Cox, 1972) . Progression-free survival (PFS) and overall survival (OS) were calculated from the date of first surgery to the date of clinical or pathological progression or death. Survival analyses were carried out using SPSS for MS Windows 6.0.
RESULTS

Western blot analysis
The level of expression of p21 was analysed by Western blot in a group of 68 primary ovarian cancers, 20 omental metastases, two LMP tumours and nine benign tumours (Figure 1 ). p21 levels were significantly higher in malignant than in benign tumours (median 2.10 i.a., range 0.12-5.00 vs median 1.22 i.a., range 0.32-2.05; P < 0.03). A statistically significant difference was found in p21 levels of omental metastases with respect to primary ovarian tumours (median 2.54 i.a., range 0.55-5.72 vs median 2.10 i.a., range 0.12-5.00; P < 0.01).
The distribution of p21 levels according to the clinicopathological parameters of 68 primary ovarian cancers is shown in 
Detection of point mutations
A total of 78 primary ovarian cancers, 12 omental metastases, two LMP and five benign tumours were screened for the presence of mutations in the K-ras gene using synthetic oligonucleotide probes after a PCR amplification step (Figure 2) . In six cases, both the omental metastasis and the corresponding primary ovarian tumour were analysed. Two normal term placentas were used as negative controls. In three cases, the ovarian cancer was bilateral and both the affected ovaries were analysed.
Of 78 ovarian cancers examined, five were found to contain ras gene mutations (6.4%), four in codon 12 and one in codon 13. Three were G-*C transversions and two G->T transversions (Table 2) .
Interestingly, all three ovarian cancer samples carrying the same G-C transversion and analysed for both p21 expression and K-ras mutation showed p21 overexpression. No data on p21 expression were available for the other two cases with ras mutations.
No point mutations of codon 12, 13 and 61 were detected in any of the 12 omental metastases or in any of the six corresponding primary tumours.
Ras gene mutations were also analysed in LMP and benign ovarian tumours. Both LMP tumours were mutated (100%) at codon 13 and carried the same mutation (G-4A transition). Activating ras mutations were also found in three of five benign tumours (60%), all in codon 12. Two were G-*T transversion and one G-4C transversion.
Considering the overall population analysed, mutations in K-ras were observed in three of five (60%) mucinous tumours, 5 of 50 (10%) serous tumours, and 2 of 22 (11%) endometrioid tumours. The higher percentage of mutations found in the mucinous histotype was statistically significant (P = 0.0152). Ras gene point mutations were not differently distributed in relation to the other clinicopathological parameters.
British Journal of Cancer (1997) 75(10), [1547] [1548] [1549] [1550] [1551] [1552] [1553] 0 Cancer Research Campaign 1997 (Hanley and McNeil, 1982) , 34 shown to be a ne patients (54%) were p21-negative and 29 patients (46%) p21-posilated by multivari tive. Figure 3 shows Figure 4 shows the PFS according to p21 status. Patients with increase in p21 le p21-negative tumours had a median PFS of 35 months, whereas are also consisten p21-positive patients had a median PFS of 16 months (P < 0.05).
related to tumour The relative risk of death was estimated in both univariate and that activated raw multivariate analysis using a backward stepwise procedure. In the (Egan et (Table 3) . (Garbisa et al, 19 NV, not valuable. CR-PR, complete response-partial tudy, which updates and extends our previous ognostic significance of ras/p21 expression in Scambia et al, 1993a), p21 overexpression is Igative independent prognostic factor. As calcuiate analysis, the association of p21 overexpressurvival was independent of other prognostic esidual disease and stage. This is consistent with that found an association between increased p21 ssion and poor prognosis in breast cancer (Giai Id et al, 1995) . Moreover, our data showing an evels in metastases compared with primary sites it with the hypothesis that p21 overexpression is aggressiveness. Several studies have suggested Ls may contribute to the metastatic phenotype '; Caulin et al, 1996) . Transfection of normal rat ,ts with activated c-H-ras caused these cells to etastatic (Thorgeirsson et al, 1985) . (1997) ras expression is inversely correlated with the expression of the NM-23 protein, which is believed to play an important role in the suppression of metastases (Scambia et al, 1996) . Our results partly differ from two previous immunohistochemical studies (Rodenburg et al, 1988; Yaginuma et al, 1992 ) that found no correlation between p21 levels and clinical outcome but are in agreement with recent work by Katsaros et al (1995) , performed by immunoblot analysis. This discrepancy may be due to the different methods employed and the use of different monoclonal antibodies -RAP-5 (Rodenburg et al, 1988) and RAP-28 (Yaginuma et al, 1992) -from the one (Y13-259) used both in our study and in that of Katsaros. RAP-5 binds to proteins of a variety of molecular weights in many different neoplastic and normal cell types, while Y13-259 does not recognize ras-related proteins and is of proven specificity to p21 ras (Robinson et al, 1986) . RAP-28 recognizes epitopes shared by H-ras and K-ras gene products, but not by N-ras-coded p21, whereas Y13-259 recognizes the epitope shared by all the activated ras gene family (Kuzumaki et al, 1986) . It is also worth noting that Yaginuma's study (1992) included only 29 patients, 14 of which were at stage I disease. The survival of these early stage patients was only 50% at 5 years, which would suggest that staging procedures were incomplete.
Although in other malignant neoplasms K-ras mutations are relatively frequent (Forrester et al, 1987; Liu et al, 1987; Bos, 1989) our data indicate that they are a rare event in ovarian carcinomas. This finding is in agreement with previous studies reporting a combined incidence of K-ras mutations of 4-14% in ovarian carcinomas (van't Veer et al, 1988; Enomoto et al, 1990 Enomoto et al, , 1991 Teneriello et al, 1993) . The frequency of K-ras mutations is particularly low in the most frequent serous histotype. On the other hand, even in the small series analysed, K-ras mutations are a frequent event in the less common mucinous carcinomas and in benign and LMP mucinous tumours. This finding, which is in line with previously reported data (Enomoto et al, 1990; Mok et al, 1993; Teneriello et al, 1993; Cuatrecasas et al, 1996) , strongly suggests that K-ras activation plays an essential role as an early genetic alteration in the pathogenesis of mucinous ovarian tumours irrespective of their malignancy. The overall low incidence of ras mutations and ras amplification (van't Veer et al, 1988; Boltz et al, 1989 ) and the lack of correlation between ras overexpression and genomic instability (evaluated as aneuploidy) do not account for the high frequency of ras/p21 overexpression that we observed. Further investigations on the mechanism responsible for ras 21 overexpression will be required to address this issue.
It has been reported (Satoh et al, 1990; Dickson et al, 1987 ) that ras/p21 is involved in the intracellular pathway through which the EGF mitogenic signal is transduced. Moreover, high levels of EGFR are associated with a particularly poor prognosis in ovarian cancer (Scambia et al, 1992; Bartlett et al, 1996) . Our data show that both ras overexpression and EGFR are independent prognostic parameters. Therefore, it is possible that the simultaneous evaluation of both EGFR and ras may provide complementary information about the presence of alterations of the ras/p21 pathway at different steps, thus improving the prognostic characterization of ovarian cancer patients.
In conclusion, the data presented in this study suggest that the assessment of p21 status at the time of initial surgery may allow the identification of a subset of patients with a particularly poor prognosis. High-risk patients could be candidates for more aggressive and/or experimental primary treatment than that conventionally used. Furthermore, the prognostic significance of p21 levels might imply that ovarian cancer is a candidate for a novel anticancer therapy based on drugs targeted directly against ras activity. Progress has already been made in the development of famesyltransferase inhibitors which block ras famesylation and abolish ras-transforming activity 'in vitro' and the growth of ras-dependent tumours in nude mice . Therefore, it would be of interest to test such compounds in patients with ovarian carcinoma overexpressing ras/p2 1.
